Keywords: United Therapeutics, Treprostinil, Ph III, PAH, Pulmonary arterial hypertension

United Thera’s oral PAH drug treprostinil fails in Ph III study

Article | 26 August 2011

US biotech firm United Therapeutics (Nasdaq: UTHR) says that preliminary results from its FREEDOM-C(2) Phase III trial of treprostinil diethanolamine ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

United Therapeutics

Go to company listing

Related Drugs

Treprostinil

Go to drug listing